0001564590-20-039478.txt : 20200812 0001564590-20-039478.hdr.sgml : 20200812 20200812070532 ACCESSION NUMBER: 0001564590-20-039478 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20200812 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200812 DATE AS OF CHANGE: 20200812 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TCR2 THERAPEUTICS INC. CENTRAL INDEX KEY: 0001750019 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 474152751 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38811 FILM NUMBER: 201094062 BUSINESS ADDRESS: STREET 1: 100 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-949-5200 MAIL ADDRESS: STREET 1: 100 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 8-K 1 tcrr-8k_20200812.htm 8-K 20Q2 EARNINGS RELEASE tcrr-8k_20200812.htm
false 0001750019 0001750019 2020-08-12 2020-08-12

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):

August 12, 2020

 

TCR2 THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

 

001-38811

 

47-4152751

(State or other jurisdiction of incorporation)

 

(Commission File Number)

 

(I.R.S Employer Identification No.)

 

100 Binney Street

Suite 710

Cambridge

MA

02142

 

(Address of Principal Executive Offices)

 

(Zip Code)

 

(617) 949-5200

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock

TCRR

The Nasdaq Stock Market, LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company  ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 2.02 Results of Operations and Financial Condition

On August 12, 2020, TCR2 Therapeutics Inc. announced its financial results for the quarter ended June 30, 2020. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Report on Form 8-K, including Exhibit 99.1, attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit No.

 

Description

99.1

 

Press release dated August 12, 2020

104

 

Inline XBRL cover page

 

 

 

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date:

August 12, 2020

 

TCR2 Therapeutics Inc.

 

 

 

 

 

 

 

 

By:

/s/ Mayur (Ian) Somaiya

 

 

 

 

Mayur (Ian) Somaiya

 

 

 

 

Chief Financial Officer

 

 

 EX-99.1 2 tcrr-ex991_6.htm EX-99.1 tcrr-ex991_6.htm

 

Exhibit 99.1

 

TCR2 Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update

 

- TC-210 patient with partial response confirmed by independent central review and tumor regression improved further from 42% to 75%

- Began dosing of TC-110 in the Phase 1/2 trial for patients with CD19+ NHL or adult ALL

- Addition of MD Anderson Cancer Center, a leading clinical site, to the TC-110 Phase 1/2 clinical trial

- Raised gross proceeds of $142.6 million in a secondary offering in July; extended cash runway into 2023

 

CAMBRIDGE, Mass., August 12, 2020 - TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced financial results for the second quarter ended June 30, 2020 and provided a corporate update.

 

“The second quarter was incredibly strong for the Company as we continued to deliver significant progress in our clinical trials of TC-210 and TC-110 despite the pandemic. We are particularly pleased to update that, following the earlier announcement of five of our first five cancer patients showing tumor regression with TC-210, one patient is now a confirmed partial response based on independent central review and experienced further tumor regression from 42% to 75%,” said Garry Menzel, Ph.D., President and Chief Executive Officer of TCR2 Therapeutics. “The initial data from TC-210 provide meaningful readthrough for our TRuC-T cell platform and we believe our robust preclinical pipeline supports our next phase of growth as we build a leading cell therapy company treating solid tumors. The strengthening of our balance sheet through our recent financing puts us in an excellent position to execute on our objectives and provide further clinical and scientific updates in 2020.”

 

Recent Developments

 

 

•

TCR2 announced positive interim data from the first five patients treated in the Phase 1 portion of the TC-210 Phase 1/2 clinical trial for mesothelin-expressing solid tumors. All five patients showed tumor regression including two with RECIST partial response, one of which is now confirmed and two patients with stable disease through six months. Translational data further demonstrated TRuC-T cell expansion and activation. A manageable toxicity profile was observed with only one patient exhibiting TC-210-related non-hematologic grade >2 toxicity and no evidence of neurotoxicity or on-target, off-tumor toxicity.

 

•

TCR2 highlighted preclinical data at the American Association for Cancer Research (AACR) Virtual Annual Meeting II of the Company’s proprietary T Cell Receptor Fusion Construct (TRuC®) T cells that co-express a PD-1:CD28 switch receptor, which acts as a cell-intrinsic mechanism to overcome PD-L1/PD-L2 mediated immunosuppression. Upon repeated antigen stimulation, co-expression of the switch receptor in mesothelin-targeting TC-210 T cells enhanced TCR downstream signaling, prevented PD-L1-mediatied functional T-cell inhibition, significantly increased proliferation and augmented the production of growth and effector cytokines.

 

•

TCR2 announced the expansion of its leadership team with key business development and regulatory affairs cell therapy experts with the appointments of Gregg McConnell as Head of Business Development and Viera Muzithras as Vice President of Regulatory Affairs.

 

 

 

Anticipated Milestones

 

 

•

TCR2 anticipates an interim update from the Phase 1 portion of the TC-210 Phase 1/2 clinical trial for patients with mesothelin-expressing solid tumors in 2H20.

 

•

TCR2 anticipates an interim update from the Phase 1 portion of the TC-110 Phase 1/2 clinical trial for patients with CD19+ non-Hodgkin lymphoma or adult acute lymphoblastic leukemia in 2H20.

 

•

TCR2 anticipates certification of its manufacturing facility in Stevenage, UK, in 2H20.

 

•

TCR2 anticipates an IND filing for a third TRuC-T cell program in 2021.

 

Financial Highlights

 

 

•

Cash Position: TCR2 ended the second quarter of 2020 with $124.8 million in cash, cash equivalents, and investments compared to $158.1 million as of December 31, 2019. As a result of the recent equity offering, TCR2 raised an additional $134.6 million. Net cash used in operations was $16.0 million for the second quarter of 2020 compared to $10.2 million for second quarter of 2019. TCR2 continues to project net cash use of $60-70 million for 2020.

 

 

•

R&D Expenses: Research and development expenses were $12.9 million for the second quarter of 2020 compared to $8.8 million for the second quarter of 2019. The increase in R&D expenses is primarily related to increase in headcount, activities related to the Phase 1/2 clinical trial of TC-210 and activities related to the Phase 1/2 clinical trial of TC-110.

 

 

•

G&A Expenses: General and administrative expenses were $3.8 million for the second quarter of 2020 compared to $3.3 million for the second quarter of 2019. The increase in general and administrative expenses was primarily due to an increase in personnel costs and costs associated with operations as a public company.

 

 

•

Net Loss: Net loss was $16.2 million for the second quarter of 2020 compared to $11.1 million for the second quarter of 2019, driven predominantly by increased R&D expenses.

 

Upcoming Events

 

TCR2 Therapeutics management is scheduled to participate at the following upcoming conferences.

 

 

•

2020 Wedbush PacGrow Healthcare Virtual Conference: Ian Somaiya, Chief Financial Officer of TCR2 Therapeutics, will provide a company update using a virtual platform on Wednesday, August 12, 2020 at 10:55am ET

 

•

Cantor Fitzgerald Virtual Global Healthcare Conference: Garry Menzel, Ph.D., President and Chief Executive Officer of TCR2 Therapeutics, and Ian Somaiya, Chief Financial Officer of TCR2 Therapeutics, will provide a company update using a virtual platform on Wednesday, September 16, 2020 at 8:40am ET

 

About TCR2 Therapeutics

 

TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors or hematological malignancies. TCR2’s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC®-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while secreting lower levels of cytokine release. The Company’s lead TRuC-T cell product candidate targeting solid tumors, TC-210, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC),

 

 

ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. The Company’s lead TRuC-T cell product candidate targeting hematological malignancies, TC-110, is currently being studied in a Phase 1/2 clinical trial to treat patients with CD19-positive adult acute lymphoblastic leukemia (aALL) and with aggressive or indolent non-Hodgkin lymphoma (NHL). For more information about TCR2, please visit www.tcr2.com.

 

Forward-looking Statements

 

This press release contains forward-looking statements and information within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "may," "will," "could", "should," "expects," "intends," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "seeks," "endeavor," "potential," "continue" or the negative of such words or other similar expressions can be used to identify forward-looking statements. These forward-looking statements include, but are not limited to, express or implied statements regarding the therapeutic potential of TC-210, future clinical development plans, the development of the Company’s TRuC-T cells, their potential characteristics, applications and clinical utility, and the potential therapeutic applications of the Company’s TRuC-T cell platform.

 

The expressed or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation: uncertainties inherent in clinical studies and in the availability and timing of data from ongoing clinical studies; whether interim results from a clinical trial will be predictive of the final results of the trial; whether results from preclinical studies or earlier clinical studies will be predictive of the results of future trials; the expected timing of submissions for regulatory approval or review by governmental authorities, including review under accelerated approval processes; orphan drug designation eligibility; regulatory approvals to conduct trials or to market products; TCR2’s ability to maintain sufficient manufacturing capabilities to support its research, development and commercialization efforts, including TCR2’s ability to secure additional manufacturing facilities; whether TCR2's cash resources will be sufficient to fund TCR2's foreseeable and unforeseeable operating expenses and capital expenditure requirements, the impact of the COVID-19 pandemic on TCR2’s ongoing operations; and other risks set forth under the caption "Risk Factors" in TCR2’s most recent Annual Report on Form 10-K, most recent Quarterly Report on Form 10-Q and its other filings with the Securities and Exchange Commission. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although TCR2 believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur.

 

Moreover, except as required by law, neither TCR2 nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Investor and Media Contact:

Carl Mauch

Director, Investor Relations and Corporate Communications

(617) 949-5667

carl.mauch@tcr2.com

 

 


 

 

TCR2 THERAPEUTICS INC.

UNAUDITED CONSOLIDATED BALANCE SHEETS

(amounts in thousands, except share data)

 

 

 

June 30, 2020

 

December 31, 2019

 

Assets

 

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

49,695

 

$

65,296

 

Investments

 

 

75,118

 

 

92,828

 

Prepaid expenses and other current assets

 

 

8,964

 

 

5,061

 

Total current assets

 

 

133,777

 

 

163,185

 

 

 

 

 

 

 

 

 

Property and equipment, net

 

 

5,957

 

 

4,926

 

Restricted cash

 

 

417

 

 

417

 

Deferred offering costs

 

 

231

 

 

-

 

Total assets

 

$

140,382

 

$

168,528

 

 

 

 

 

 

 

 

 

Liabilities and stockholders’ equity (deficit)

 

 

 

 

 

 

 

Accounts payable

 

$

2,987

 

$

2,483

 

Accrued expenses and other current liabilities

 

 

3,373

 

 

5,050

 

Total current liabilities

 

 

6,360

 

 

7,533

 

 

 

 

 

 

 

 

 

Other liabilities

 

 

609

 

 

546

 

Total liabilities

 

 

6,969

 

 

8,079

 

 

 

 

 

 

 

 

 

Stockholders’ equity (deficit)

 

 

 

 

 

 

 

Common stock, $0.0001 par value; 150,000,000 shares authorized; 24,139,510 and 24,050,936 shares issued; 24,104,595 and 23,981,109 shares outstanding at June 30, 2020 and December 31, 2019, respectively.

 

 

2

 

 

2

 

Additional paid-in capital

 

 

347,351

 

 

342,896

 

Accumulated other comprehensive income (loss)

 

 

402

 

 

142

 

Accumulated deficit

 

 

(214,342

)

 

(182,591

)

Total stockholders’ equity (deficit)

 

 

133,413

 

 

160,449

 

Total liabilities, redeemable convertible preferred stock, and stockholders’ equity (deficit)

 

$

140,382

 

$

168,528

 

 


 

 

TCR2 THERAPEUTICS INC.

UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS

(amounts in thousands, except share and per share data)

 

 

 

Three Months Ended

June 30,

 

 

Six Months Ended

June 30,

 

 

 

2020

 

 

2019

 

 

2020

 

 

2019

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

$

12,907

 

 

$

8,833

 

 

$

24,862

 

 

$

16,722

 

General and administrative

 

 

3,809

 

 

 

3,307

 

 

 

8,080

 

 

 

6,193

 

Total operating expenses

 

 

16,716

 

 

 

12,140

 

 

 

32,942

 

 

 

22,915

 

Loss from operations

 

 

(16,716

)

 

 

(12,140

)

 

 

(32,942

)

 

 

(22,915

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income, net

 

 

499

 

 

 

1,077

 

 

 

1,246

 

 

 

1,949

 

Loss before income taxes

 

 

(16,217

)

 

 

(11,063

)

 

 

(31,696

)

 

 

(20,966

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income taxes

 

 

28

 

 

 

-

 

 

 

55

 

 

 

-

 

Net loss

 

 

(16,245

)

 

 

(11,063

)

 

 

(31,751

)

 

 

(20,966

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accretion of redeemable convertible preferred stock to redemption value

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(49,900

)

Net loss attributable to common stockholders

 

$

(16,245

)

 

$

(11,063

)

 

$

(31,751

)

 

$

(70,866

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Per share information

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss per share of common stock, basic and diluted

 

$

(0.67

)

 

$

(0.46

)

 

$

(1.32

)

 

$

(3.91

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares outstanding, basic and diluted

 

 

24,075,984

 

 

 

23,818,003

 

 

 

24,043,913

 

 

 

18,105,142

 

 


 

 

 

TCR2 THERAPEUTICS INC.

UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS

(amounts in thousands)

 

 

Six Months Ended June 30,

 

 

2020

 

 

2019

 

Operating activities

 

 

 

 

 

 

 

Net loss

$

(31,751

)

 

$

(20,966

)

Adjustments to reconcile net loss to cash used in operating activities:

 

 

 

 

 

 

 

Depreciation and amortization

 

673

 

 

 

300

 

Stock-based compensation expense

 

4,119

 

 

 

2,585

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

Prepaid expenses and other current assets

 

(3,904

)

 

 

(3,735

)

Accounts payable

 

29

 

 

 

180

 

Accrued expenses and other liabilities

 

(1,587

)

 

 

646

 

Cash used in operating activities

 

(32,421

)

 

 

(20,990

)

 

 

 

 

 

 

 

 

Investing activities

 

 

 

 

 

 

 

Purchases of equipment

 

(1,229

)

 

 

(941

)

Purchases of investments

 

(63,005

)

 

 

(106,566

)

Proceeds from sale or maturity of investments

 

80,975

 

 

 

42,619

 

Cash provided by (used in) investing activities

 

16,741

 

 

 

(64,888

)

 

 

 

 

 

 

 

 

Financing activities

 

 

 

 

 

 

 

Proceeds from initial public offering, net of issuance costs

 

-

 

 

 

80,213

 

Proceeds from the exercise of stock options

 

310

 

 

 

18

 

Deferred offering costs

 

(231

)

 

 

(1,047

)

Cash provided by financing activities

 

79

 

 

 

79,184

 

 

 

 

 

 

 

 

 

Net change in cash, cash equivalents, and restricted cash

 

(15,601

)

 

 

(6,694

)

Cash, cash equivalents, and restricted cash at beginning of year

 

65,713

 

 

 

47,964

 

Cash, cash equivalents, and restricted cash at end of period

$

50,112

 

 

$

41,270

 

# # #

 

 GRAPHIC 3 g0gop33dtbyd000001.jpg GRAPHIC begin 644 g0gop33dtbyd000001.jpg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end EX-101.SCH 4 tcrr-20200812.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 tcrr-20200812_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Title of 12(b) Security Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name EX-101.PRE 6 tcrr-20200812_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 tcrr-8k_20200812_htm.xml IDEA: XBRL DOCUMENT 0001750019 2020-08-12 2020-08-12 false 0001750019 8-K 2020-08-12 TCR2 THERAPEUTICS INC. DE 001-38811 47-4152751 100 Binney Street Suite 710 Cambridge MA 02142 617 949-5200 false false false false Common Stock TCRR NASDAQ true false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Document and Entity Information
Aug. 12, 2020
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 12, 2020
Entity Registrant Name TCR2 THERAPEUTICS INC.
Entity Central Index Key 0001750019
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity File Number 001-38811
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 47-4152751
Entity Address, Address Line One 100 Binney Street
Entity Address, Address Line Two Suite 710
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02142
City Area Code 617
Local Phone Number 949-5200
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol TCRR
Security Exchange Name NASDAQ
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.tcr2.com/20200812/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports tcrr-8k_20200812.htm tcrr-20200812.xsd tcrr-20200812_lab.xml tcrr-20200812_pre.xml tcrr-ex991_6.htm http://xbrl.sec.gov/dei/2019-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tcrr-8k_20200812.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "tcrr-8k_20200812.htm" ] }, "labelLink": { "local": [ "tcrr-20200812_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "tcrr-20200812_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "tcrr-20200812.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "tcrr", "nsuri": "http://www.tcr2.com/20200812", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "tcrr-8k_20200812.htm", "contextRef": "C_0001750019_20200812_20200812", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.tcr2.com/20200812/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "tcrr-8k_20200812.htm", "contextRef": "C_0001750019_20200812_20200812", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tcr2.com/20200812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tcr2.com/20200812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tcr2.com/20200812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tcr2.com/20200812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tcr2.com/20200812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tcr2.com/20200812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tcr2.com/20200812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tcr2.com/20200812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tcr2.com/20200812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tcr2.com/20200812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tcr2.com/20200812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-US": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tcr2.com/20200812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tcr2.com/20200812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tcr2.com/20200812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tcr2.com/20200812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tcr2.com/20200812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tcr2.com/20200812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tcr2.com/20200812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tcr2.com/20200812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tcr2.com/20200812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tcr2.com/20200812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tcr2.com/20200812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tcr2.com/20200812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tcr2.com/20200812/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 15 0001564590-20-039478-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-20-039478-xbrl.zip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